ZS Pharma to Present at the 21st Annual BioCentury NewsMakers Conference
September 17, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, Sept. 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Presents New Data From ZS003 a Two Week Phase 3 Trial Demonstrating That ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi
September 15, 2014 18:30 ET
|
ZS Pharma
COPPELL, Texas, Sept. 15, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma to Present Data From Phase 3 Trial of ZS-9 in Late-Breaking Session at Heart Failure Society of America 18th Annual Scientific Meeting
September 11, 2014 08:00 ET
|
ZS Pharma
COPPELL, Texas, Sept. 11, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma to Present Late-Breaking Abstract Data from Phase 3 Trial of ZS-9 in State of the Art and Featured Research Session Oral Presentation at European Society of Cardiology (ESC) Congress
August 26, 2014 08:30 ET
|
ZS Pharma
COPPELL, Texas, Aug. 26, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Announces Second Quarter 2014 Financial Results
August 14, 2014 16:30 ET
|
ZS Pharma
COPPELL, Texas, Aug. 14, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
ZS Pharma Secures $20 Million in Debt Financing
July 17, 2014 08:00 ET
|
ZS Pharma
COPPELL, Texas, July 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today...
ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients With Hyperkalemia
July 14, 2014 16:00 ET
|
ZS Pharma
COPPELL, Texas, July 14, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders,...
ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9
July 08, 2014 08:00 ET
|
ZS Pharma
COPPELL, Texas, July 8, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it...